A Double-Blind, Placebo-Controlled, Single Dose and Multiple Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YA-101 in Healthy Subjects

开始日期2023-10-12

申办/合作机构-

100 项与 YA-101 相关的临床结果

登录后查看更多信息

100 项与 YA-101 相关的转化医学

登录后查看更多信息

100 项与 YA-101 相关的专利（医药）

登录后查看更多信息

项与 YA-101 相关的文献（医药）

2011-04-01·Drug Metabolism and Disposition2区 · 医学

Pharmacokinetics, Metabolism, and Disposition of Rivoglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, in Rats and Monkeys

2区 · 医学

Article

作者: Takahashi, Makoto ; Izumi, Takashi ; Abe, Koji ; Uchiyama, Minoru ; Tsuruta, Fujiko ; Okazaki, Osamu ; Oguchi, Minoru ; Iwabuchi, Haruo ; Koda, Hiroko

The pharmacokinetics, metabolism, and excretion of rivoglitazone [(RS)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione monohydrochloride], a novel thiazolidinedione (TZD) peroxisome proliferator-activated receptor γ selective agonist, were evaluated in male F344/DuCrlCrlj rats and cynomolgus monkeys. The total body clearance and volume of distribution of rivoglitazone were low in both animals (0.329-0.333 ml per min/kg and 0.125-0.131 l/kg for rats and 0.310-0.371 ml per min/kg and 0.138-0.166 l/kg for monkeys), and the plasma half-life was 4.55 to 4.84 h for rats and 6.21 to 6.79 h for monkeys. The oral bioavailability was high (>95% in rats and >76.1% in monkeys), and the exposure increased dose proportionally. After administration of [(14)C]rivoglitazone, radioactivity was mainly excreted in feces in rats, whereas radioactivity was excreted in urine and feces with the same ratio in monkeys. Because excreted rivoglitazone in urine and bile was low, metabolism was predicted to be the main contributor to total body clearance. The structures of 20 metabolites (M1-M20) were identified, and 5 initial metabolic pathways were proposed: O-demethylation, TZD ring opening, N-glucuronidation, N-demethylation, and TZD ring hydroxylation. O-Demethylation was the main metabolic pathway in both animals, but N-demethylation and TZD ring hydroxylation were observed only in monkeys. N-Glucuronide (M13) was nonenzymatically hydrolyzed to TZD ring-opened N-glucuronide (M9), and the amount of these metabolites in monkeys was larger than that in rats. In plasma, rivolitazone was observed as the main component in both animals, and O-demethyl-O-sulfate (M11) was observed as the major metabolite in rats but as many minor metabolites in monkeys.

2010-08-01·Journal of Pharmacology and Experimental Therapeutics3区 · 医学

E3710, a New Proton Pump Inhibitor, with a Long-Lasting Inhibitory Effect on Gastric Acid Secretion

3区 · 医学

Article

作者: Miyazawa, Shuhei ; Kawahara, Tetsuya ; Kubota, Atsuhiko ; Terauchi, Hiroki ; Shinoda, Masanobu ; Iida, Daisuke ; Murota, Miki ; Sou, Yasui ; Fujisaki, Hideaki ; Tabata, Yoshikuni ; Watanabe, Nobuhisa ; Kodama, Kotaro ; Kuramochi, Hiroko ; Kato, Hiroshi ; Harada, Hitoshi ; Hirota, Kazuo ; Nagakawa, Junichi ; Ueda, Masato

We have investigated the pharmacology of sodium (R)-2-[4-(2,2-dimethyl-1,3-dioxan-5-yl) methoxy-3,5-dimethylpyridin-2-yl]methylsulfinyl-1H-benzimidazol (E3710), a new proton pump inhibitor (PPI), and its effect on gastric acid secretion. E3710 irreversibly inhibited H(+),K(+)-ATPase activity in pig gastric vesicles with an acidic internal environment with an IC(50) of 0.28 microM. Administration of E3710 (0.1, 0.2, 0.4, and 0.8 mg/kg; n = 6) intraduodenally in a gastric fistula model in dogs inhibited histamine-stimulated gastric acid secretion at 0 to 2 and 24 to 26 h after administration with ED(50) values of 0.18 and 0.22 mg/kg, respectively. The inhibition by E3710 was 2.3 times more potent than that of another representative PPI, esomeprazole (0.2, 0.4, 0.8, and 1.6 mg/kg; n = 6) at 0 to 2 h after administration (ED(50) = 0.40 mg/kg) and 2.8 times more potent at 24 to 26 h (ED(50) = 0.71 mg/kg). In the gastric fistula dogs, the intragastric pH was >or=4 for 17% (n = 27) of a 24-h period with vehicle alone, but when E3710 was administered, at 0.2 (n = 4), 0.4 (n = 8), and 0.8 mg/kg (n = 5), the pH was >or=4 for 40, 79, and 88% of a day, respectively. The corresponding values for esomeprazole at 0.8 (n = 4) and 1.6 mg/kg (n = 8) were 55 and 59%, respectively. In a crossover study with vehicle, E3710 at 0.4 mg/kg and esomeprazole at 1.6 mg/kg (n = 6), E3710 increased the intragastric pH to >4 for 82% of a day compared with 61% of a day with esomeprazole. These results show that E3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease.

2010-02-18·Journal of Pharmacy and Pharmacology3区 · 医学

The Long-lasting Effect of TU-199, a Novel H+,K+-ATPase Inhibitor, on Gastric Acid Secretion in Dogs

3区 · 医学

Article

作者: Wakatsuki, Daisuke ; Araki, Tsutomu ; Uchiyama, Kazuyuki ; Kakinoki, Bunpei ; Takeuchi, Yoshishige ; Morinaka, Yasuhiro

AbstractWe have used Heidenhain-pouch dogs to investigate the effects of (±)-5-methoxy-2-{[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulphinyl}-1H-imidazo[4,5-b]pyridine (TU-199), an imidazopyridine derivative, on gastric acid secretion stimulated by histamine, carbachol and tetragastrin. We have also investigated the duration of the antisecretory effect of TU-199 using a measurement of intragastric pH for 24 h in gastric fistula dogs whose gastric acid secretion was stimulated by histamine.Single oral administration of TU-199 (0.1, 0.2 and 0.4 mg kg−1) dose-dependently suppressed gastric acid secretion stimulated by histamine infusion. Oral treatment with TU-199 (0.2, 0.4 and 0.8 mg kg−1) also dose-dependently inhibited acid secretion induced by carbachol and tetragastrin. The inhibitory effect of TU-199 on stimulated gastric acid secretion was more potent than that of omeprazole, a well-known H+,K+-ATPase inhibitor in dogs. Repeated oral treatment with TU-199 at a dose of 0.2 mg kg−1 once a day for seven days markedly suppressed histamine-stimulated gastric acid secretion in dogs. This inhibitory effect of TU-199 reached a maximum level after three or four doses and was more pronounced than that of omeprazole or lansoprazole. In gastric fistula dogs, the duration of intragastric pH-elevation by administration of TU-199 (0.3 mg kg−1) was much longer than that of omeprazole (0.6 mg kg−1) or lansoprazole (0.9 mg kg−1). The IC50 values (doses resulting in 50% inhibition) of TU-199, omeprazole and lansoprazole with regard to H+,K+-ATPase activity in dog gastric mucosal microsomes were 8.6, 8.8 and 9.9 μM, respectively.These results indicate that TU-199 inhibits gastric acid secretion via suppression of a H+,K+-ATPase activity. Our findings also suggest that TU-199 might have potent and long-lasting effects on gastric acid secretion.

100 项与 YA-101 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多系统萎缩	临床1期	澳大利亚	Yoda Pharmaceuticals, Inc.初创企业	2023-10-12
阿尔茨海默症	临床前	-	Yoda Pharmaceuticals, Inc.初创企业	2023-03-02
精神分裂症	临床前	-	Yoda Pharmaceuticals, Inc.初创企业	2023-03-02